Tracers / [161Tb]Tb-DOTA-LM3
[161Tb]Tb-DOTA-LM3
Also written as [Tb-161]Tb-DOTA-LM3
- Radionuclide
- Tb-161 t½ 9907.2 min
- Modality
- Therapy
- Production route
- —
- Stage
- Phase 0 clinical study
- Syntheses indexed
- 3
What it is
- Compound class
- DOTA-conjugated somatostatin receptor antagonist peptide
- Target / mechanism
- Somatostatin receptor (SSTR) antagonist PMID 39046521
- Clinical application
- Peptide receptor radionuclide therapy of somatostatin receptor-positive neuroendocrine tumours PMID 41381241
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| — | — | SPE | — | at least 95% | DOTA-LM3 | 41381241 2026 J Nucl Med [161Tb]Tb-DOTA-LM3 was manufactured by radiolabeling 100 µg of DOTA-LM3 with [161Tb]TbCl3 using an automated synthesis module. |
| Manual synthesis | — | none | — | >98% | DOTA-LM3 CSBio, California, US | 39046521 2024 Eur J Nucl Med Mol Imaging DOTA-LM3 (CSBio, Silicon Valley Menlo Park, California, United States) and DOTATATE (Bachem, Bubendorf, Switzerland) were labeled with terbium-161 or lutetium-177 at a molar activity of up to 100 MBq/nmol using standard labeling conditions as previously reported |
| — | — | — | — | ≥ 98% | DOTA-LM3 | 34625828 2022 Eur J Nucl Med Mol Imaging |
Need this precursor?We can point you to suppliers for [161Tb]Tb-DOTA-LM3, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 4 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 41381241: 'DOTA-LM3'. Stage set/updated at stage 23 from PMID 41381241: 'A Phase 0 Study.'.